Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of tralokinumab in atopic dermatitis
2018-000746-19Phase 3Active
- Sponsor
- LEO Pharma
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoint: Number of adverse events (AEs). Started Aug 2018; status: active.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-000746-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000746-19.